We serve Chemical Name:fluorocyclohexane CAS:372-46-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:fluorocyclohexane
CAS.NO:372-46-3
Synonyms:monofluorocyclohexane;Cyclohexane,fluoro;EINECS 206-754-9;Fluor-cyclohexan;cyclohexylfluoride;fluoro-cyclohexane;MFCD00021285;Fluorocyclohexane;1-fluorocyclohexane
Molecular Formula:C6H11F
Molecular Weight:102.15000
HS Code:2903890090
Physical and Chemical Properties:
Melting point:13°C
Boiling point:103 °C
Density:0,928 g/cm3
Index of Refraction:1.4146
PSA:
Exact Mass:102.08400
LogP:2.28860
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:3272
Packing Group:II
Contact us for information like monofluorocyclohexane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-fluorocyclohexane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-fluorocyclohexane Use and application,EINECS 206-754-9 technical grade,usp/ep/jp grade.
Related News: It comes as AZ’s flagship EGFR inhibitor Tagrisso has just been included for national reimbursement in China in the front-line setting. [2-[(8S,10S,13S,14S,16S,17R)-17-hydroxy-10,13,16-trimethyl-3-oxo-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] benzoate manufacturers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 8,9,10,11-tetrahydro-7H-azepino[1′,2′:1,2]imidazo[4,5-g]quinoline suppliers Anifrolumab is a fully human monoclonal antibody that binds to subunit 1 of the type I interferon receptor, blocking the activity of type I interferons. 3-(4-methanesulfonyl-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 8,9,10,11-tetrahydro-7H-azepino[1′,2′:1,2]imidazo[4,5-g]quinoline suppliers Anifrolumab is a fully human monoclonal antibody that binds to subunit 1 of the type I interferon receptor, blocking the activity of type I interferons. 3-(4-methanesulfonyl-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine vendor & factory.
